Mustang Bio Overview
Company Headquarters: Massachusetts, US
Founded: 2015
Workforce: ~370+
Company Working: Mustang Bio is a subsidiary of Fortress Biotech, Inc. It is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to leverage the patient’s immune system to eliminate cancer cells. Mustang Bio aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, funding research and development, and out-licensing or bringing the technologies to market. Mustang has partnered with the City of Hope National Medical Center (COH) and Fred Hutchinson Cancer Research Center in the development of proprietary CAR T therapies for many cancers. Mustang Bio’s lead programs are in Phase 1 clinical trials at COH: MB-101 for the treatment of brain cancer and MB-102 as a therapeutic agent in acute myeloid leukemia
Strategy
Mustang Bio focuses on licensing its technologies that support preclinical and clinical research activities to its partners and transfer the underlying technology to its cell processing facility in Massachusetts in order to conduct Mustang sponsored clinical trials.
